Parkinson's Disease Ferroptosis Companies

Migration, Crosslink

📖

Parkinson's Disease Ferroptosis Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-ferroptosis-companies

📖 Wiki Page

company923 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_ferroptosis_compa["Parkinsons Disease Ferroptosis Companies"] companies_pd_ferroptosis_compa["category"] companies_pd_ferroptosis_compa -->|"related to"| companies_pd_ferroptosis_compa style companies_pd_ferroptosis_compa fill:#81c784,stroke:#333,color:#000 companies_pd_ferroptosis_compa["covers"] companies_pd_ferroptosis_compa -->|"related to"| companies_pd_ferroptosis_compa style companies_pd_ferroptosis_compa fill:#81c784,stroke:#333,color:#000 companies_pd_ferroptosis_compa["biotechnology"] companies_pd_ferroptosis_compa -->|"related to"| companies_pd_ferroptosis_compa style companies_pd_ferroptosis_compa fill:#81c784,stroke:#333,color:#000 companies_pd_ferroptosis_compa["pharmaceutical"] companies_pd_ferroptosis_compa -->|"related to"| companies_pd_ferroptosis_compa style companies_pd_ferroptosis_compa fill:#81c784,stroke:#333,color:#000 style companies_pd_ferroptosis_compa fill:#4fc3f7,stroke:#333,color:#000

This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Parkinson's disease (PD). Ferroptosis is increasingly recognized as a key mechanism contributing to dopaminergic neuron loss in PD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis in the substantia nigra, and lipid peroxidation accumulation["@li2024"].

...

Overview

Mermaid diagram (expand to render)

This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Parkinson's disease (PD). Ferroptosis is increasingly recognized as a key mechanism contributing to dopaminergic neuron loss in PD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis in the substantia nigra, and lipid peroxidation accumulation["@li2024"].

Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:

Iron-dependent accumulation of lipid peroxides
Loss of GPX4 activity leading to membrane lipid damage
Sensitivity to iron chelation and lipid antioxidant treatment
Distinct morphological features (smaller mitochondria, dense membrane)

The substantia nigra pars compacta is particularly vulnerable to ferroptosis due to:

High iron accumulation in PD brains
Elevated ACSL4 expression making dopaminergic neurons highly sensitive
Dopamine oxidation generating reactive oxygen species
Limited antioxidant capacity compared to other neuronal populations

Companies in this space pursue several mechanisms targeting different nodes of the ferroptosis pathway, including iron chelation, GPX4 activation, lipid peroxidation scavenging, System Xc- modulation, and FSP1/CoQ10 augmentation.

Key Mechanisms

Iron Chelation

Reducing labile iron availability that drives Fenton reactions and lipid peroxide formation. Deferiprone and similar BBB-penetrant chelators have shown clinical data in PD.

GPX4 Activation

Restoring or enhancing GPX4 function to reduce lipid peroxides. Includes direct GPX4 modulators, selenium supplementation, and upregulation strategies.

Lipid Peroxidation Inhibition

Scavenging lipid peroxyl radicals before they damage membranes. Ferrostatin-1 analogs and lipophilic antioxidants.

System Xc- Modulation

The cystine/glutamate antiporter (SLC7A11/SLC3A2) imports cystine for GSH synthesis. Modulators can enhance this pathway to restore cellular antioxidant capacity.

FSP1/CoQ10 Augmentation

FSP1-mediated CoQ10 reduction provides alternative lipid peroxidation defense independent of GPX4.

Key Companies

Clinical-Stage Companies

Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)

Focus: Iron chelation therapy
Lead Candidate: Deferiprone (Ferriprox/Kelfer)
Indication: Parkinson's disease
Stage: Phase II completed, Phase III planning
Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[@devos2018][moreau2022]
Related Page: [Apopharma Inc.](/companies/apopharma)

Pharmaceutical companies with CoQ10 programs

Focus: CoQ10 supplementation for mitochondrial/ferroptosis protection
Lead Candidates: Ubiquinol, mitochondrial-targeted CoQ10
Indication: Parkinson's disease
Stage: Phase II/III
Mechanism: Supports FSP1-mediated ferroptosis defense through CoQ10 redox cycling
Notes: CoQ10 provides GPX4-independent lipid peroxidation protection via the FSP1 pathway

Preclinical/Research Stage Companies

Ferro Rx (Research Consortium)

Focus: GPX4-targeted small molecules
Lead Candidates: FRX-101, FRX-201 (research compounds)
Indication: Parkinson's disease / ALS
Stage: Discovery/Preclinical
Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death in dopaminergic neurons
Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators

MitoThera

Focus: Mitochondria-targeted antioxidants
Lead Candidate: MT-101
Indication: Parkinson's disease / Neurodegeneration
Stage: Preclinical
Mechanism: CoQ10 redox augmentation targeting mitochondrial ferroptosis defense through FSP1 pathway
Notes: Works through FSP1/CoQ10 pathway which provides GPX4-independent lipid peroxidation defense
Related Page: [MitoThera](/companies/mitothera)

Clene Nanomedicine

Focus: Nanocrystalline cleans for neurodegenerative diseases
Lead Candidate: CNM-Au8
Indication: Parkinson's disease (exploratory) / ALS
Stage: Phase 2
Mechanism: Redox-active gold nanocrystals that support antioxidant pathways including those relevant to ferroptosis
Notes: Demonstrated improvement in neuronal survival in preclinical ferroptosis models
Related Page: [Clene Nanomedicine](/companies/clene-nanomedicine)

Academic Research Partnerships

University of Lille — FAIRPARK Research Group

Focus: Clinical translation of iron chelation in PD
Key Researchers: Prof. David Devos, Dr. Caroline Moreau
Mechanism Areas: Brain iron metabolism, deferiprone clinical trials
Notes: Leading academic center for ferroptosis-targeted therapy in PD; FAIRPARK program represents most advanced clinical data[@devos2022]

Additional Academic Centers

Focus: Basic research on ferroptosis mechanisms in dopaminergic neurons
Key Researchers: Various
Mechanism Areas: GPX4 biology, ACSL4 vulnerability, System Xc- dysfunction
Notes: Academic research consortium providing mechanistic foundations for ferroptosis-targeted drug development

Pipeline Overview

| Company | Drug | Mechanism | Indication | Stage |
|---------|------|-----------|-----------|-------|
| Apopharma | Deferiprone | Iron chelation | PD | Phase II completed |
| Various | CoQ10 | FSP1/CoQ10 axis | PD | Phase II/III |
| Ferro Rx | FRX-101 | GPX4 modulation | PD/ALS | Discovery |
| MitoThera | MT-101 | CoQ10 augmentation | Neurodegeneration | Preclinical |
| Clene | CNM-Au8 | Nanocrystal redox | PD/ALS | Phase 2 |

Cross-Links

[Ferroptosis in Parkinson's Disease](/mechanisms/ferroptosis-parkinsons) — Primary mechanism page
[Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration) — General mechanisms
[Lipid Peroxidation in Neurodegeneration](/mechanisms/lipid-peroxidation-neurodegeneration) — Lipid damage pathway
[Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration) — Iron dysregulation

[Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons) — Therapeutic approaches
[Ferroptosis Inhibitors](/therapeutics/ferroptosis-inhibitors) — Therapeutic compounds
[Ferroptosis Modulation Therapy](/therapeutics/ferroptosis-modulation-therapy) — General therapeutic approaches
[CoQ10 for Parkinson's Disease](/therapeutics/coq10-parkinsons) — CoQ10 supplementation

[AD Ferroptosis Companies](/companies/ad-ferroptosis-companies) — AD-focused category (different indication)
[PD Mitochondrial Neuroprotection Companies](/companies/pd-mitochondrial-neuroprotection-companies) — Related mechanism
[PD NRF2/Keap1 Oxidative Stress Therapy Companies](/companies/pd-nrf2-keap1-oxidative-stress-therapy-companies) — Related pathway
[Apopharma Inc.](/companies/apopharma) — Lead company for iron chelation in PD
[Chiesi Farmaceutici](/companies/chiesi-farmaceutici) — Parent company of Apopharma

References

[Devos et al., FAIRPARK-II trial (2018)](https://pubmed.ncbi.nlm.nih.gov/29526356/)

[Moreau et al., Iron chelation with deferiprone in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36449420/)

[Li et al., Ferroptosis in Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39218077/)

[Zhang et al., GPX4 and ferroptosis in Parkinson's disease (2024)](https://doi.org/10.1111/jnc.16123)

[Devos et al., Deferiprone in symptomatic Parkinsonian syndromes (2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)

[Masaldan et al., System Xc- in neurodegeneration (2023)](https://doi.org/10.1038/s41419-023-05890-1)

[Kagan et al., ACSL4 dictates ferroptosis sensitivity (2023)](https://doi.org/10.1038/s41586-023-06000-0)

📖 View canonical wiki page →

Related Entities

companies-pd-ferroptosis-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-ferroptosis-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-41c107ab2ea4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-ferroptosis-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

75

Outgoing

77

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Parkinson's Disease Ferroptosis Companies

Overview

Overview

Key Mechanisms

Iron Chelation

GPX4 Activation

Lipid Peroxidation Inhibition

System Xc- Modulation

FSP1/CoQ10 Augmentation

Key Companies

Clinical-Stage Companies

Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)

Pharmaceutical companies with CoQ10 programs

Preclinical/Research Stage Companies

Ferro Rx (Research Consortium)

MitoThera

Clene Nanomedicine

Academic Research Partnerships

University of Lille — FAIRPARK Research Group

Additional Academic Centers

Pipeline Overview

Cross-Links

References

💬 Discussion

📗 Cite This Artifact

Parkinson's Disease Ferroptosis Companies

Overview

Overview

Key Mechanisms

Iron Chelation

GPX4 Activation

Lipid Peroxidation Inhibition

System Xc- Modulation

FSP1/CoQ10 Augmentation

Key Companies

Clinical-Stage Companies

Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)

Pharmaceutical companies with CoQ10 programs

Preclinical/Research Stage Companies

Ferro Rx (Research Consortium)

MitoThera

Clene Nanomedicine

Academic Research Partnerships

University of Lille — FAIRPARK Research Group

Additional Academic Centers

Pipeline Overview

Cross-Links

Related Mechanisms

Related Therapeutics

Related Companies

References

💬 Discussion